Main navigation

APEx was a CIP-ICT-PSP project under which national archival institutions from 33 European countries and the International Centre for Archival Research have released a new version of the Internet portal for documents and archives in Europe.The APEx consortium partners decided to transfer the results developed to a new entity – the Archives Portal Europe Foundation (APEF). A number of questions needed clarification and a common understanding among partners before the transfer occurs – the identification of the results and their respective owners.

This case study is an example of exploitation of project outcomes through the creation of a new legal entity.

Every day there are many good ideas and research results that are put aside due to inappropriate innovation strategies.

This case study, based on the direct experience of Tapointel S.L., demonstrates how an SME can succeed in managing innovation and setting up an effective patent application strategy with the support of a European IPR Helpdesk Ambassador.

Classification

We are pleased to inform you that a new issue of the European IPR Helpdesk Bulletin has been released and is now available online.

Does your business have know-how, inventions or brands? Then you have intangible assets that can be brought to the market to create new revenues and increase profits.

This Bulletin issue is largely dedicated to IP Commercialisation comprising the different available mechanisms to realise economic values from Intellectual Property (IP).

Particular attention is given to licensing as the most common IP commercialisation tool presenting specificities depending on the Intellectual Property involved.

An insight on licensing and Standard Essential Patents (SEPs) is offered by an article of Mr Matteo Sabattini and Ms Alessandra Mosca from Sisvel.

Read our interviews to discover the point of view of European SMEs on IP management and commercialisation.

As always, the Bulletin reports information about past IPR events together with some fresh news on the Helpline service. In addition, it contains the usual patent quiz and a new IP commercialisation crossword.

Successful industries survive on continuous innovation, bringing to the market new products and services by developing or acquiring cutting-edge technology. The process of acquiring the rights related to a third party’s technology through a licence agreement is indicated as technology licensing-in.

This fact sheet analyses the most relevant issues related to technology licensing-in, giving readers an overview of the preliminary steps and practical suggestions to follow in order to get prepared for future negotiations.

You want to commercialise your products with the support of external business partners? The story of this Italian SME, Celegon Srl, teaches us how crucial it is to take confidentiality measures and IP protection into consideration before entering into any business partnership.

The Organisation for Economic Co-operation and Development (OECD) and the European Union Intellectual Property Office (EUIPO) join forces once again to shed some light on an intellectual property matter with a great impact in the European Union economy: the sale of counterfeited goods.

Under the title "Why do countries export fakes?", this new report analyses the drivers that will make an economy more likely to become active in the trade of fake goods, with the ultimate purpose of enlightening policy makers so that they develop efficient policy responses to tackle the issue.

The European Commission (EC) is proposing a targeted adjustment to IP rules to help Europe's pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

The EC proposes a targeted amendment: the so-called 'export manufacturing waiver' to Supplementary Protection Certificates (SPCs). The waiver will support Europe's pioneering role in pharmaceutical research and development.

Thanks to the waiver:

in the future EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, if done exclusively for the purpose of exporting to a non-EU market where protection has expired or never existed.

IP protection for medicine production in Europe will remain the strongest in the world. SPC-protected medicines will retain their full market exclusivity in the EU.